Free tool
FAERS Monitor: Scenesse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210797 or its brand name (Scenesse, Afamelanotide). Reports on generic versions are filed under their own applications.
Reports
21
Serious
17
81% of reports
Hospitalization
9
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic reaction4
- contraindication to medical treatment3
- type i hypersensitivity3
- implant site hypersensitivity2
- implant site pruritus2
- implant site urticaria2
- malignant melanoma2
- vomiting2
- acute kidney injury1
- acute on chronic liver failure1
- appendicitis1
- ascites1
- asthenia1
- cellulitis1
- death1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| implant site urticaria | 2 | 20887.0 | 5505.5 | 23,016 |
| implant site hypersensitivity | 2 | 18395.9 | 4857.6 | 20,320 |
| acute on chronic liver failure | 1 | 4663.2 | 685.4 | 1,159 |
| implant site pruritus | 2 | 2232.9 | 596.5 | 2,504 |
| contraindication to medical treatmentSignal | 3 | 1971.0 | 690.5 | 4,093 |
| type i hypersensitivitySignal | 3 | 854.5 | 299.6 | 1,774 |
| malignant melanoma | 2 | 149.6 | 40.0 | 165 |
| appendicitis | 1 | 107.2 | 15.8 | 26 |
| anaphylactic reactionSignal | 4 | 72.5 | 30.0 | 216 |
| ascites | 1 | 34.1 | 5.0 | 8 |
| cellulitis | 1 | 19.9 | 2.9 | 4 |
| acute kidney injury | 1 | 6.5 | 1.0 | 1 |
| vomiting | 2 | 4.3 | 1.1 | 2 |
| asthenia | 1 | 2.7 | 0.4 | 0 |
| death | 1 | 1.2 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.